Overview

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
0
Participant gender:
Male
Summary
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Watson Pharmaceuticals
Treatments:
Silodosin
Criteria
Inclusion Criteria:

- Males in good general health and at least 50 years of age, with symptoms of moderate
to severe benign prostatic hyperplasia.

Exclusion Criteria:

- Medical conditions that would confound the efficacy evaluation.

- Medical conditions in which it would be unsafe to use an alpha-blocker.

- The use of concomitant drugs that would confound the efficacy evaluation.

- The use of concomitant drugs that would be unsafe with this alpha-blocker.